{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:57:15Z","timestamp":1790351835618,"version":"4.1.0"},"reference-count":71,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Based on small numbers, recent reports from 3 randomized trials have consistently demonstrated more hematologic malignancies in patients treated with lenalidomide as maintenance (vs placebo). This fact has prompted concern and highlighted the association between multiple myeloma and second malignancies. Furthermore, an excess of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after multiple myeloma has been known for over 4 decades. Most prior studies have been restricted because of small numbers of patients, inadequate follow-up, and limitations of ascertainment of second malignancies. Although the underlying biologic mechanisms of AML\/MDS after multiple myeloma are unknown, treatment-related factors are presumed to be responsible. Recently, an excess risk of AML\/MDS was found among 5652 patients with IgG\/IgA (but not IgM) monoclonal gammopathy of undetermined significance, supporting a role for disease-related factors. Furthermore, there is evidence to suggest that polymorphisms in germline genes may contribute to a person's susceptibility to subsequent cancers, whereas the potential influence of environmental and behavioral factors remains poorly understood. This review discusses current knowledge regarding second malignancies after multiple myeloma and gives future directions for efforts designed to characterize underlying biologic mechanisms, with the goal to maximize survival and minimize the risk for second malignancies for individual patients.<\/jats:p>","DOI":"10.1182\/blood-2011-12-381426","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T07:52:15Z","timestamp":1328601135000},"page":"2731-2737","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":100,"title":["Second malignancies after multiple myeloma: from 1960s to 2010s"],"prefix":"10.1182","volume":"119","author":[{"given":"Anish","family":"Thomas","sequence":"first","affiliation":[{"name":"Multiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Korde","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurdur Y.","family":"Kristinsson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar","family":"Turesson","sequence":"additional","affiliation":[{"name":"Division of Medicine, Skane University Hospital, Malmo, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111811062294400_B1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.","volume":"28","author":"Turesson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111811062294400_B2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"15","key":"2019111811062294400_B3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111811062294400_B4","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/jnci\/dji278","article-title":"Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2019111811062294400_B5","first-page":"33","article-title":"Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.","volume":"1","author":"Mauch","year":"1995","journal-title":"Cancer J"},{"issue":"3","key":"2019111811062294400_B6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J Clin Oncol"},{"key":"2019111811062294400_B7","volume-title":"New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000","author":"Curtis","year":"2006"},{"key":"2019111811062294400_B8","first-page":"178","article-title":"Myelomatosis: a clinical review of 310 cases.","volume":"445","author":"Nordenson","year":"1996","journal-title":"Acta Med Scand Suppl"},{"key":"2019111811062294400_B9","first-page":"573","volume-title":"Gamma Globulins: Structure and Control of Biosynthesis","author":"Osserman","year":"1967"},{"issue":"21","key":"2019111811062294400_B10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJM197011192832101","article-title":"Multiple myeloma and acute myelomonocytic leukemia.","volume":"283","author":"Kyle","year":"1970","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111811062294400_B11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","article-title":"The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia.","volume":"301","author":"Bergsagel","year":"1979","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111811062294400_B12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4065\/mcp.2009.0426","article-title":"Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.","volume":"85","author":"Turesson","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2019111811062294400_B13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1034\/j.1600-0609.2000.90218.x","article-title":"Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma.","volume":"65","author":"Finnish Leukaemia Group","year":"2000","journal-title":"Eur J Haematol"},{"issue":"7","key":"2019111811062294400_B14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms.","volume":"85","author":"Dong","year":"2001","journal-title":"Br J Cancer"},{"issue":"15","key":"2019111811062294400_B15","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precursor disease (MGUS).","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"key":"2019111811062294400_B16","unstructured":"Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, second edition to International Classification of Diseases for Oncology, 3rd ed. Cancer Statistics Branch, DCCPS, SEER Program, National Cancer Institute. 2001 [cited 2011 July 22]. Available at http:\/\/seer.cancer.gov\/tools\/conversion\/ICDO2-3manual.pdf"},{"issue":"1","key":"2019111811062294400_B17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jnci\/djj001","article-title":"Cancer survivorship: genetic susceptibility and second primary cancers: research strategies and recommendations.","volume":"98","author":"Travis","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2019111811062294400_B18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/10428194.2010.529207","article-title":"Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma.","volume":"52","author":"Hasskarl","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111811062294400_B19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2007-06-097444","article-title":"Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.","volume":"111","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111811062294400_B20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.bmt.1705814","article-title":"Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma.","volume":"40","author":"Przepiorka","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111811062294400_B21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2141.1996.d01-1891.x","article-title":"Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma.","volume":"95","author":"Govindarajan","year":"1996","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111811062294400_B22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1987.107","article-title":"A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis: a report to the Medical Research Council's working party on leukaemia in adults.","volume":"55","author":"Cuzick","year":"1987","journal-title":"Br J Cancer"},{"issue":"2","key":"2019111811062294400_B23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-103-2-195","article-title":"Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.","volume":"103","author":"Pedersen-Bjergaard","year":"1985","journal-title":"Ann Intern Med"},{"issue":"3","key":"2019111811062294400_B24","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-105-3-360","article-title":"Melphalan may be a more potent leukemogen than cyclophosphamide.","volume":"105","author":"Greene","year":"1986","journal-title":"Ann Intern Med"},{"issue":"2","key":"2019111811062294400_B25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/cncr.20755","article-title":"Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: II. Leukemia and myeloma.","volume":"103","author":"Featherstone","year":"2005","journal-title":"Cancer"},{"issue":"45","key":"2019111811062294400_B26","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/sj.onc.1206989","article-title":"Second cancers after radiotherapy: any evidence for radiation-induced genomic instability?","volume":"22","author":"Sigurdson","year":"2003","journal-title":"Oncogene"},{"issue":"4","key":"2019111811062294400_B27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries.","volume":"12","author":"de Gonzalez","year":"2011","journal-title":"Lancet Oncol"},{"issue":"8","key":"2019111811062294400_B28","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2007.11.9081","article-title":"Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.","volume":"26","author":"Schaapveld","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111811062294400_B29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.bjc.6605435","article-title":"Second solid cancers after radiotherapy for breast cancer in SEER cancer registries.","volume":"102","author":"Berrington de Gonzalez","year":"2010","journal-title":"Br J Cancer"},{"key":"2019111811062294400_B30","article-title":"Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial.","author":"Attal"},{"key":"2019111811062294400_B31","doi-asserted-by":"crossref","article-title":"Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma CALGB ECOG BMT-CTN 100104.","author":"McCarthy","DOI":"10.1200\/jco.2010.28.15_suppl.8017"},{"key":"2019111811062294400_B32","first-page":"29","article-title":"Incidence of second primary malignancy in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance in newly diagnosed multiple myeloma patients age 65 or older [abstract].","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111811062294400_B33","doi-asserted-by":"crossref","article-title":"Incidence and characteristics of secondary myelodysplastic syndrome developing during lenalidomide-based regimens in relapsed and\/or refractory multiple myeloma patients.","author":"Reece","DOI":"10.1182\/blood.V116.21.1877.1877"},{"key":"2019111811062294400_B34","first-page":"29","article-title":"Lenalidomide and dexamethasone treatment in relapsed\/refractory multiple myeloma patients and risk of second primary malignancies: analysis of MM-009\/010 [abstract].","author":"Dimopoulos","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111811062294400_B35","first-page":"119","article-title":"Lenalidomide treatment is not eelated to AML progression risk but is associated with a survival benefit in RBC transfusion-dependent patients with IPSS low- or Int-1-risk MDS with del5q: results from a comparative study.","volume":"118","author":"Kuendgen","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"8","key":"2019111811062294400_B36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2019111811062294400_B37","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/sj.leu.2404330","article-title":"The role of cytogenetics in myeloma.","volume":"20","author":"Zhan","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"2019111811062294400_B38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00008571-199808000-00001","article-title":"Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research.","volume":"8","author":"Kalow","year":"1998","journal-title":"Pharmacogenetics"},{"issue":"6","key":"2019111811062294400_B39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics: drug disposition, drug targets, and side effects.","volume":"348","author":"Evans","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111811062294400_B40","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/ijc.24940","article-title":"GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis.","volume":"126","author":"Dahabreh","year":"2010","journal-title":"Int J Cancer"},{"issue":"12","key":"2019111811062294400_B41","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nrc1749","article-title":"Mechanisms of therapy-related carcinogenesis.","volume":"5","author":"Allan","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019111811062294400_B42","first-page":"1814","article-title":"Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation.","volume":"94","author":"Abruzzese","year":"1999","journal-title":"Blood"},{"issue":"9","key":"2019111811062294400_B43","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/sj.leu.2401116","article-title":"Clonal myelodysplastic cells present in apheresis product before transplantation.","volume":"12","author":"Amigo","year":"1998","journal-title":"Leukemia"},{"key":"2019111811062294400_B44","doi-asserted-by":"crossref","article-title":"Characteristics of patients presenting with secondary myelodysplastic syndrome during treatment with lenalidomide for relapsed\/refractory multiple myeloma: 5q deletions can be observed.","author":"Goswami","DOI":"10.1182\/blood.V116.21.1876.1876"},{"issue":"11","key":"2019111811062294400_B45","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del(5q) myelodysplasia in remission.","volume":"363","author":"Tehranchi","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111811062294400_B46","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.011528","article-title":"Clonal heterogeneity in the 5q\u2212 syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.","volume":"94","author":"Jadersten","year":"2009","journal-title":"Haematologica"},{"issue":"10","key":"2019111811062294400_B47","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood.V84.10.3253.3253","article-title":"The 5q\u2212syndrome.","volume":"84","author":"Boultwood","year":"1994","journal-title":"Blood"},{"issue":"26","key":"2019111811062294400_B48","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1182\/blood-2010-04-273771","article-title":"Advances in the 5q\u2212 syndrome.","volume":"116","author":"Boultwood","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111811062294400_B49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2010.11.008","article-title":"Multiple myeloma precursor disease: current clinical dilemma and future opportunities.","volume":"48","author":"Landgren","year":"2011","journal-title":"Semin Hematol"},{"issue":"22","key":"2019111811062294400_B50","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1182\/blood-2008-10-183244","article-title":"Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.","volume":"113","author":"Knight","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111811062294400_B51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2007-11-126508","article-title":"MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.","volume":"112","author":"Ellis","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111811062294400_B52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1535-6108(02)00032-6","article-title":"Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.","volume":"1","author":"Yeoh","year":"2002","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111811062294400_B53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jama.1990.03450050059028","article-title":"Cancer risk among atomic bomb survivors: the RERF Life Span Study. Radiation Effects Research Foundation.","volume":"264","author":"Shimizu","year":"1990","journal-title":"JAMA"},{"key":"2019111811062294400_B54","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.2307\/3578893","article-title":"Cancer incidence in atomic bomb survivors. III. Leukemia, lymphoma and multiple myeloma, 1950-1987.","volume":"137","author":"Preston","year":"1994","journal-title":"Radiat Res"},{"issue":"4","key":"2019111811062294400_B55","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1200\/JCO.2010.31.3080","article-title":"Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors.","volume":"29","author":"Iwanaga","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111811062294400_B56","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood-2008-05-159665","article-title":"Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors.","volume":"113","author":"Iwanaga","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111811062294400_B57","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood-2008-11-186957","article-title":"A role for ionizing radiation in myelomagenesis?","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111811062294400_B58","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/oem.2009.054809","article-title":"The relationship between multiple myeloma and occupational exposure to six chlorinated solvents.","volume":"68","author":"Gold","year":"2011","journal-title":"Occup Environ Med"},{"issue":"1","key":"2019111811062294400_B59","first-page":"33","article-title":"A case-control study of multiple myeloma in Japan: association with occupational factors.","volume":"6","author":"Sonoda","year":"2005","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"2019111811062294400_B60","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111811062294400_B61","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3324\/haematol.2009.008979","article-title":"Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"issue":"21","key":"2019111811062294400_B62","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111811062294400_B63","article-title":"Commentary: does immune suppression increase risk of developing acute myeloid leukemia? [published online ahead of print August 26, 2011]","author":"Gale","journal-title":"Leukemia"},{"issue":"12","key":"2019111811062294400_B64","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1200\/JCO.2008.18.2006","article-title":"Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in Sweden.","volume":"27","author":"Kristinsson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111811062294400_B65","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/0145-2126(92)90077-K","article-title":"Alcohol consumption and risk of leukemia, non-Hodgkin's lymphoma, and multiple myeloma.","volume":"16","author":"Brown","year":"1992","journal-title":"Leuk Res"},{"issue":"4","key":"2019111811062294400_B66","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.beha.2007.08.001","article-title":"Epidemiology of the plasma-cell disorders.","volume":"20","author":"Kyle","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"2019111811062294400_B67","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/BF01694762","article-title":"Obesity and multiple myeloma.","volume":"5","author":"Friedman","year":"1994","journal-title":"Cancer Causes Control"},{"issue":"7","key":"2019111811062294400_B68","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","article-title":"Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111811062294400_B69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1008937901586","article-title":"Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States.","volume":"12","author":"Brown","year":"2001","journal-title":"Cancer Causes Control"},{"issue":"23","key":"2019111811062294400_B70","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMc1111010","article-title":"Myeloma and second primary cancers.","volume":"365","author":"Landgren","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111811062294400_B71","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0002-9343(67)90164-7","article-title":"Extraosseous lesion in plasma cell myeloma. A report of six cases.","volume":"43","author":"Edwards","year":"1967","journal-title":"Am J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/12\/2731\/1350080\/zh801212002731.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/12\/2731\/1350080\/zh801212002731.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T02:43:22Z","timestamp":1713494602000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/12\/2731\/29823\/Second-malignancies-after-multiple-myeloma-from"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,22]]},"references-count":71,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,3,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-12-381426","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,22]]}}}